TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chest Ultrasound of ER Patients With Cough or SOB

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Presenting to the Emergency Department with cough, wheezing and/or dyspnea (shortness of breath)~* Referred for CXR and/or CT scan~Exclusion Criteria:~* Life threatening medical condition requiring immediate treatment~* Unable to sit up for a chest ultrasound~* Unable to consent~* Pregnant~* Unable to speak, read and write in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be 18 years of age or older~2. Patients must present to clinic with a diagnosis of benign prostatic hyperplasia with lower urinary tract symptoms~3. Patients must be scheduled to undergo a holmium laser prostate surgery (enucleation or ablation)~Exclusion Criteria:~1. Patients who are under 18 years of age are not eligible.~2. Patients who have a diagnosis of bladder cancer are not eligible.~3. Patient who have a diagnosis of prostate cancer are not eligible.~4. Patients with an elevated prostate-specific antigen (PSA) suggesting prostate cancer are not eligible unless patient has prior negative prostate biopsy.~5. Patients who have acute prostatitis, a prostate abscess, or neurogenic bladder are not eligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Long Term Medication Usage (Type: None): Patients who have been on medication for over a year for benign prostatic hyperplasia (BPH)
- Short Term Medication Usage (Type: None): Patients who have been on medication for under a year for benign prostatic hyperplasia (BPH)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CHiropractic for Infantile Colic Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Parentally-reported crying of more than three hours per day for three or more days in the preceding week (reported at initial contact to determine preliminary diagnosis of colic)~* Confirmation at first clinic visit that the infant has cried for more than three hours per day for at least one day in the base-lining period.~* Otherwise normal infants, born at term, with normal growth and development, and no indication of other underlying pathology~* Parents fluent in English, providing informed written consent~Exclusion Criteria:~* Infants who have received previous chiropractic, osteopathic or other manipulative treatment

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 12 Weeks
- Healthy Volunteers: f

Study Arms:
- Best standard care only - not blind (Type: ACTIVE_COMPARATOR): Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice.~Parents aware that infant is not receiving chiropractic treatment
- Best Standard Care and Sham - Blind (Type: SHAM_COMPARATOR): Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus sham chiropractic treatment. Parents unaware of whether infant is receiving real treatment or sham.
- BSC & Chiropractic - Not blind (Type: EXPERIMENTAL): Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents aware that infant is receiving chiropractic treatment.
- BSC & Chiropractic - Blind (Type: EXPERIMENTAL): Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents not aware that infant is receiving chiropractic treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Omega-3 Fatty Acid Supplementation in Acne Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female above 18 years of age.~* Moderate to severe disease at the baseline of the study identified by their dermatologist.~* Will start treatment with systemic therapy for acne in the form of either isotretinoin or oral antibiotics.~* Patients able and willing to comply with the procedures in the study protocol.~Exclusion Criteria:~* Patients with history of taking omega-3 supplements for high triglyceride levels.~* Patients taking medications for dyslipidemia, blood thinners, or high blood pressure medication.~* Patients with a history of adverse reaction to omega-3 fatty acid supplementation.~* Unwilling to give inform consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- O3FA (Type: EXPERIMENTAL): Omega 3 Fatty Acid 1200mg twice a day for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 4 tablets twice a day for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Pain and Hydration After Tonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing tonsillectomy~* Patients undergoing tonsillectomy with adenoidectomy~Exclusion Criteria:~* Patients on anticoagulants~* Patients younger than 3 years old~* Patients with chronic pain syndrome

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 98 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Patients in the control group will not be given any special fluids to take after surgery Patients will use their discretion to drink as needed following surgery
- Hoist (Type: EXPERIMENTAL): Patients in the Hoist group will be given a 10 day supply of Hoist that they will self administer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
1. Male and female adult patients (age ≥ 20 years old)~2. Patients diagnosed with unresectable HCC \[Child Pugh class A and major vascular invasion, extrahapatic metastasis, or progression after transarterial chemoembolization more than 2 times\]~3. Presence of mRECIST target lesion within liver \[lesion which can be classified as a RECIST measurable lesion (can be measured ≥ 1 cm in at least one dimension), lesion suitable for repeated measure, lesion showing intraluminal arterial enhancement on contrast-enhanced CT or MRI\]~4. Patients planned to be treated with sorafenib~5. Patient with liver CT performed or planned to be performed within 4 weeks before initiation of sorafenib treatment~6. Patient with a life expectancy of 12 weeks or more~7. No previous treatment with sorafenib~8. Female patients who are surgically sterilized, or post-menopausal (minimum 12 months of amenorrhea) or who have a documented negative urine hCG test at screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadoterate meglumine (Type: EXPERIMENTAL): there is one single arm of patients (no comparative arm)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Recent acute coronary syndrome with ongoing ticagrelor treatment~* Stabilized clinical condition with no plans of additional revascularization~* Dyspnea with onset after start of ticagrelor treatment~* Willingness to abstain from caffeine intake (e.g. coffee, tea, cola-type beverages; other foods, nutritional supplements or medications containing caffeine) for the duration of the study~* Provision of signed informed consent form~Exclusion Criteria:~* Chronic obstructive pulmonary disease, asthma or other known pulmonary disease requiring daily medical therapy~* Obstructive sleep apnea syndrome requiring therapy~* Ongoing signs and symptoms of heart failure\*, or evidence of moderately to severely reduced left ventricular (LV) function~* Renal failure, glomerular filtration rate (GFR) \<30 or on dialysis~* Pregnancy or lactation~* Known allergy to ticagrelor, or caffeine, or known intolerance of caffeine~* Ongoing treatment with any of the following: quinolone antibiotics, fluvoxamine, phenylpropanolamine, carbamazepine, clozapine, lithium, non-steroidal anti-inflammatory drugs (NSAIDs); or any drug containing theophylline or caffeine.~* Any condition that seriously increases the risk of non-compliance or loss of follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caffeine (Type: EXPERIMENTAL): Caffeine capsules. 200 mg twice daily orally for 7-10 days.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsules twice daily orally for 7-10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ECG negative for acute MI~* Must be low to intermediate risk for ACS based on the initial ECG, history, and physical, in the absence of ischemic ECG changes and positive markers.~* Must be likely to have stress MPI or coronary arteriography as part of the diagnostic evaluation.~Exclusion Criteria:~* Creatinine \> 1.5 mg/dL~* Allergy to radiographic contrast~* Pregnancy~* Contraindication to beta-blocker administration~* Inability to hold breath for 12 seconds~* Inability to place an 18-gauge IV angiocatheter in an antecubital vein~* Arrhythmia that will preclude gating of the CTA~* Prior bypass surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ED patients undergoing coronary CTA (Type: None): Emergency Department patients suspected of having acute coronary syndrome undergoing Coronary Computed Tomographic angiography.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must meet all of the following clinical criteria for MCI due to AD or mild AD and must have:~* A Clinical Dementia Rating (CDR)-Global Score of 0.5.~* Objective evidence of cognitive impairment at screening~* An MMSE score between 24 and 30 (inclusive)~* Must have a positive amyloid Positron Emission Tomography (PET) scan~* Must consent to apolipoprotein E (ApoE) genotyping~* If using drugs to treat symptoms related to AD, doses must be stable for at least 8 weeks prior to screening visit 1~* Must have a reliable informant or caregiver~Key Exclusion Criteria:~* Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment~* Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year~* Clinically significant unstable psychiatric illness in past 6 months~* History of unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within 1 year prior to Screening~* Indication of impaired renal or liver function~* Have human immunodeficiency virus (HIV) infection~* Have a significant systematic illness or infection in past 30 days~* Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities~* Any contraindications to brain magnetic resonance imaging (MRI) or PET scans~* Alcohol or substance abuse in past 1 year~* Taking blood thinners (except for aspirin at a prophylactic dose or less)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): Monthly intravenous (IV) infusions
- High Dose (Type: EXPERIMENTAL): Monthly intravenous (IV) infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: BicepsTenodesis vs. Biceps Debridement in Combined RC Tears and SLAP Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults over 35 years of age presenting with a high grade partial-thickness or full-thickness RC tear associated with a degenerative SLAP tear and a normal biceps tendon, confirmed by appropriate imaging, that can be surgically repaired using an arthroscopic approach will be eligible for the study.~Exclusion Criteria:~* Subjects presenting with pulley involvement, high grade full-thickness RC tears (\>3cm), biceps pathology, previous surgery to the affected shoulder, history of shoulder dislocation, inflammatory disease, or moderate to severe degenerative glenohumeral arthropathy (Kellgren-Lawrence Grade 3 or 4), major shoulder joint trauma, infection, or avascular necrosis will be excluded. Furthermore, those with psychiatric illness, cognitive impairment, or health conditions that preclude informed consent, life expectancy of less than 1 year, who do not speak/read/understand English, have no fixed address or contact, or are unwilling to complete follow-ups will also be excluded

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biceps Tenodesis (Type: EXPERIMENTAL): Patients in this group will received biceps tenodesis intervention to address their labral lesion
- Debridement (Type: ACTIVE_COMPARATOR): Patients in this group will received debridement intervention to address their labral lesion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Merging of Endoscopic and Ultrasound Images for Laparoscopic Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* of-age patient~* patient for whom a radical prostatectomy is planned~* patient with a prostate volume between 30g and 100g~* patient affiliated to the social security or equivalent~* Written informed consent~Exclusion Criteria:~* contraindication~* patient who has undergone a significant prostate resection~* patient who has undergone a prostate irradiation~* patient concerned by the L1121-6 à 8 of the health public code

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- medical device (Type: EXPERIMENTAL): medical device to acquire ultrasound and endoscopic images during surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient with solitary ureteral stone ranging from 5mm to 15mm diameter~* able to tolerate general anesthesia~* clinical indication for treatment by ureteroscopic lithotripsy~* must be willing and able to participate in any follow-up visits~* provide informed consent~* have a CT scan demonstrating the stone~Exclusion Criteria:~* patients undergoing extracorporeal shock wave lithotripsy (ESWL) or any other extracorporeal or percutaneous lithotripsy procedure as primary procedure~* any co-morbidity or condition that would necessitate exclusion of patient (physician opinion)~* renal or ureteral anatomical abnormality~* multiple stones in the indicated ureter~* stones in the indicated kidney~* patient is immunocompromised~* multiple organ dysfunction syndrome~* has an absolute or relative solitary kidney mass~* \>= Stage 3 chronic kidney disease~* bilateral ureteral obstructing stones~* staghorn calculi~* impaction of several stone fragments (Steinstrasse)~* uncorrected coagulopathy/thrombocytopenia~* urethral and/or ureteral stricture~* reconstructive urinary surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BackStop (Type: EXPERIMENTAL): Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
- Control (Type: NO_INTERVENTION): Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant with GD1 currently being treated with an ERT/SRT other than VPRIV for at least 6 months before baseline enrolment; or participant previously treated with another ERT/ SRT for at least 6 months prior to transitioning to VPRIV..~* Participant or legally authorized representative has provided written informed consent.~Exclusion Criteria:~* In the opinion of the investigator, participant is at high risk of non-compliance.~* In the opinion of the investigator, participant is unsuitable in any other way to participate in this study.~* Participant is pregnant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VPRIV Participants (Type: None): Participants who has been transitioned from ERTs/SRTs to VPRIV, the data will be collected retrospectively from time of transition until the point at which participant begins in this study and then will be followed up prospectively for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues